Linagliptin Add-on to Insulin Background Therapy

Summary

To evaluate the efficacy and safety of linagliptin compared to placebo when added on to insulin therapy alone or in combination with metformin in Chinese patients with type 2 diabetes mellitus with insufficient glycaemic control

Timeline

Start

2016-09-30

Primary completion

2019-01-11

Completion

2019-01-18

Outcome

Met primary endpoint

registry analysis (superiority test); Placebo Matching Linagliptin vs Linagliptin; p = 0.0016; Adjusted Mean Difference (%) -0.40 (95% CI -0.65 to -0.16) NCT02897349 ↗

Drugs

Indications